TXG - 10x Genomics, Inc.
NEXT EARNINGS:
May 14, 2026
EPS Est: $-0.28
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$20.29
DETAILS
HIGH:
$22.00
LOW:
$17.00
MEDIAN:
$20.00
CONSENSUS:
$20.29
UPSIDE:
6.23%
Market Cap:
2.44B
Volume:
2,186,129
Avg Volume:
2,556,288
52 Week Range:
6.78-23.56
Sector:
Healthcare
Industry:
Medical - Healthcare Information Services
Beta:
2.24
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,306
IPO Date:
2019-09-12
EPS (TTM):
-0.35
P/E Ratio:
-46.73
Revenue (TTM):
642.82M
Total Assets:
1.04B
Total Debt:
157.74M
Cash & Equiv:
473.97M
Rev Growth (5Y):
16.6%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-12.5%
Debt/Equity:
0.20
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $-0.13 | $-0.19 | +31.6% | $166.0M | $160.4M | +3.5% |
| 2025-11-06 | $-0.22 | $-0.07 | -214.3% | $149.0M | $142.5M | +4.6% |
| 2025-08-07 | $0.28 | $-0.35 | +180.0% | $172.9M | $139.5M | +23.9% |
| 2025-05-08 | $-0.36 | $-0.45 | +20.0% | $154.9M | $145.3M | +6.6% |
| 2025-02-12 | $-0.40 | $-0.29 | -37.9% | $165.0M | $165.0M | 0.0% |
| 2024-10-29 | $-0.30 | $-0.34 | +11.8% | $151.7M | $153.3M | -1.1% |
| 2024-08-08 | $-0.32 | $-0.47 | +31.9% | $153.1M | $150.1M | +2.0% |
| 2024-04-30 | $-0.50 | $-0.46 | -8.7% | $141.0M | $142.2M | -0.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 642.82M | 610.78M | 618.73M | 516.41M | 490.49M | 298.85M | 245.89M | 146.31M | 71.08M |
| Net Income | (43.54M) | (182.63M) | (255.10M) | (166.00M) | (58.22M) | (542.73M) | (31.25M) | (112.48M) | (18.76M) |
| EPS | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | -1.62 |
| Total Assets | 1.04B | 918.64M | 965.14M | 1.03B | 1.02B | 929.34M | 605.92M | 124.31M | 75.61M |
| Total Debt | 157.74M | 82.61M | 95.37M | 95.18M | 81.98M | 62.98M | 29.72M | 29.68M | 10.56M |
| Cash & Equivalents | 473.97M | 344.07M | 359.28M | 219.75M | 587.45M | 663.60M | 424.17M | 65.08M | 47.86M |
| Operating Cash Flow | 136.05M | 6.66M | (15.20M) | (33.61M) | (21.37M) | (217.90M) | 34.63M | (76.41M) | (10.70M) |
| Free Cash Flow | 130.12M | (5.73M) | (64.72M) | (165.27M) | (122.65M) | (256.29M) | (8.14M) | (83.12M) | (14.46M) |
| FCF per Share | 1.04 | -0.05 | -0.55 | -1.45 | -1.11 | -2.53 | -0.21 | -6.21 | -1.25 |
| Book Value | 796.33M | 710.13M | 741.04M | 805.74M | 817.57M | 739.07M | 420.08M | (219.99M) | (112.51M) |
| Cash & ST Investments | 523.41M | 393.40M | 388.69M | 429.98M | 587.45M | 663.60M | 424.17M | 65.08M | 47.86M |
| ROC Equity | -0.05 | -0.26 | -0.34 | -0.21 | -0.07 | -0.73 | -0.07 | N/A | N/A |